5 Key Takeaways

• 1

  GLP-1 receptor agonists like semaglutide and tirzepatide are increasingly used for diabetes, obesity, and cardiovascular disease.

• 2

  Rapid glycemic improvement with GLP-1 therapy may worsen diabetic retinopathy, particularly in patients with preexisting conditions.

• 3

  Evidence on GLP-1's impact on age-related macular degeneration is conflicting, with some studies showing both risks and benefits.

• 4

  Studies suggest an increased risk of nonarteritic anterior ischemic optic neuropathy among semaglutide users, though results are inconsistent.

• 5

  Current evidence does not warrant withholding GLP-1 therapy due to ocular safety concerns, but monitoring is advised for high-risk patients.